Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Impact · against what's priced in

Prime Medicine's first-in-human clinical data for PM359 validates the Prime Editing platform's safety and efficacy, specifically highlighting the advantage of avoiding double-strand breaks. This serves as a critical de-risking event for the company's entire pipeline beyond the specific CGD indication.

PRME+0.80

No priced-in read yet